Get started
Author

S. Jeson Sangaralingham

Observed names: S J Sangaralingham, S Jeson Sangaralingham, S. J Sangaralingham, S. J. Sangaralingham, S. Jeson M. Sangaralingham, S. Sangaralingham, S.J. Sangaralingham, S. Jeson Sangaralingham, Sangaralingham, Sasantha Jeson, Sasantha J. Sangaralingham
Institution: Mayo Clinic
Observed institutions: Marche Polytechnic University, Oslo University Hospital, Mayo Clinic, University of Oslo, Queen's University, The Alfred Hospital, Queens University, Istituto Nazionale di Riposo e Cura per Anziani, Monash University
ORCID: 0000-0002-3967-8703
Observed ORCID: 0000-0002-3967-8703
OpenAlex ID: A5050737891
Renin–Angiotensin Blockade Combined With Natriuretic Peptide System Augmentation
2013 · Thomas G. von Lueder, S. Jeson Sangaralingham, et al. · Circulation Heart Failure · 131
PDF
The Aging Heart, Myocardial Fibrosis, and its Relationship to Circulating C-Type Natriuretic Peptide
2010 · S. Jeson Sangaralingham, Brenda K. Huntley, et al. · Hypertension · 117
Cardiorenal syndrome: Multi‐organ dysfunction involving the heart, kidney and vasculature
2020 · Feby Savira, Ruth Magaye, et al. · British Journal of Pharmacology · 96
PDF
Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure
2018 · Lindsey R. Sangaralingham, S. Jeson Sangaralingham, et al. · Circulation Heart Failure · 92
Circulating Aldosterone and Natriuretic Peptides in the General Community
2014 · Alessia Buglioni, Valentina Cannone, et al. · Hypertension · 85
Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection
2011 · Fernando L. Martin, Paul M. McKie, et al. · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · 84
Natriuretic peptide pathways in heart failure: further therapeutic possibilities
2022 · S Jeson Sangaralingham, Michaela Kuhn, et al. · Cardiovascular Research · 78
PDF
Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction
2019 · Nicholas Y. Tan, Lindsey R. Sangaralingham, et al. · JACC Heart Failure · 67
Predictive Utility of Atrial, N-Terminal Pro-Atrial, and N-Terminal Pro-B-Type Natriuretic Peptides for Mortality and Cardiovascular Events in the General Community: A 9-Year Follow-up Study
2011 · Paul M. McKie, Alessandro Cataliotti, et al. · Mayo Clinic Proceedings · 67
PDF
Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis
2012 · Tomoko Ichiki, Guido Boerrigter, et al. · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · 66
CD-NP: A Novel Engineered Dual Guanylyl Cyclase Activator with Anti-Fibrotic Actions in the Heart
2012 · Fernando L. Martin, S. Jeson Sangaralingham, et al. · PLoS ONE · 65
PDF
Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: Regulation and therapeutic implications
2014 · Tomoko Ichiki, John A. Schirger, et al. · Journal of Molecular and Cellular Cardiology · 59
Differential Regulation of ANP and BNP in Acute Decompensated Heart Failure: Deficiency of ANP
2019 · Shawn H. Reginauld, Valentina Cannone, et al. · JACC Heart Failure · 58
PDF
Discovery of O-glycans on atrial natriuretic peptide (ANP) that affect both its proteolytic degradation and potency at its cognate receptor
2019 · Lasse H. Hansen, Thomas Daugbjerg Madsen, et al. · Journal of Biological Chemistry · 52
PDF
Pro–B-Type Natriuretic Peptide-1-108 Processing and Degradation in Human Heart Failure
2014 · Brenda K. Huntley, Sharon M. Sandberg, et al. · Circulation Heart Failure · 52
PDF
A Novel Atrial Natriuretic Peptide Based Therapeutic in Experimental Angiotensin II Mediated Acute Hypertension
2010 · Paul M. McKie, Alessandro Cataliotti, et al. · Hypertension · 47
First-in-Human Study of MANP: A Novel ANP (Atrial Natriuretic Peptide) Analog in Human Hypertension
2021 · Horng H. Chen, Siu-Hin Wan, et al. · Hypertension · 46
Circulating C-Type Natriuretic Peptide and Its Relationship to Cardiovascular Disease in the General Population
2015 · S. Jeson Sangaralingham, Paul M. McKie, et al. · Hypertension · 44
Cardiorenal fibrosis and dysfunction in aging: Imbalance in mediators and regulators of collagen
2016 · S. Jeson Sangaralingham, Bing H. Wang, et al. · Peptides · 43
CD-NP: An Innovative Designer Natriuretic Peptide Activator of Particulate Guanylyl Cyclase Receptors for Cardiorenal Disease
2010 · Paul M. McKie, S. Jeson Sangaralingham, et al. · Current Heart Failure Reports · 42
A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure
2017 · Rika Kawakami, Candace Y.W. Lee, et al. · Clinical Pharmacology & Therapeutics · 39
PDF
Cardiac Micro–Computed Tomography Imaging of the Aging Coronary Vasculature
2012 · S. Jeson Sangaralingham, Erik L. Ritman, et al. · Circulation Cardiovascular Imaging · 38
A Higher Foci Density of Interstitial Fibrosis and Tubular Atrophy Predicts Progressive CKD after a Radical Nephrectomy for Tumor
2021 · Luisa Ricaurte Archila, Aleksandar Denic, et al. · Journal of the American Society of Nephrology · 37
Urinary C-Type Natriuretic Peptide
2013 · Rosita Zakeri, S. Jeson Sangaralingham, et al. · JACC Heart Failure · 37
PDF
Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4‐Year Follow‐Up
2015 · Alessia Buglioni, Valentina Cannone, et al. · Journal of the American Heart Association · 36
PDF
Works count: 142
Citation count: 2,075
H-index: 30
I10-index: 43
Year
Topic
Type